ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 170 filers reported holding ALLOGENE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $296,433 | -35.4% | 93,512 | +1.3% | 0.00% | – |
| Q2 2023 | $458,582 | -2.3% | 92,270 | -2.9% | 0.00% | – |
| Q1 2023 | $469,340 | -16.9% | 95,008 | +5.8% | 0.00% | – |
| Q4 2022 | $564,887 | -42.0% | 89,807 | -0.4% | 0.00% | – |
| Q3 2022 | $974,000 | -85.7% | 90,191 | -84.9% | 0.00% | -100.0% |
| Q2 2022 | $6,820,000 | +808.1% | 598,165 | +624.6% | 0.00% | – |
| Q1 2022 | $751,000 | +35.1% | 82,553 | +121.9% | 0.00% | – |
| Q4 2021 | $556,000 | -38.4% | 37,201 | +6.0% | 0.00% | – |
| Q3 2021 | $902,000 | -12.3% | 35,110 | -10.9% | 0.00% | – |
| Q2 2021 | $1,028,000 | +37.6% | 39,411 | +86.1% | 0.00% | – |
| Q1 2021 | $747,000 | +45.6% | 21,175 | +4.2% | 0.00% | – |
| Q4 2020 | $513,000 | +9.6% | 20,327 | +63.5% | 0.00% | – |
| Q3 2020 | $468,000 | -13.2% | 12,431 | -1.4% | 0.00% | – |
| Q2 2020 | $539,000 | +101.9% | 12,607 | -8.2% | 0.00% | – |
| Q1 2020 | $267,000 | – | 13,730 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VV Manager LLC | 1,798,163 | $76,997,000 | 67.53% |
| Wildcat Capital Management, LLC | 1,515,524 | $64,895,000 | 22.42% |
| TPG Group Holdings (SBS) Advisors, Inc. | 19,716,306 | $844,252,000 | 14.91% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 1,279,281 | $54,779,000 | 7.69% |
| Coastal Bridge Advisors, LLC | 463,117 | $19,831,000 | 6.33% |
| DSAM Partners (London) Ltd | 235,098 | $10,067,000 | 2.63% |
| Casdin Capital, LLC | 625,000 | $26,763,000 | 1.58% |
| Alpine Global Management, LLC | 150,000 | $6,423,000 | 1.13% |
| Perceptive Advisors | 1,543,790 | $66,105,000 | 1.07% |
| Avoro Capital Advisors LLC | 1,128,594 | $48,326,000 | 0.96% |